Valion Bio agrees to sell 1,500 Series B preferred shares to 3i for $1.5 million in private placement
VBIO•Private placement terms
Valion Bio entered a $1.5 million private placement with 3i, LP, issuing 1,500 Series B Non-Voting Convertible Preferred shares.
- Shares were priced at $1,000 each.
- Series B Warrants to buy common stock were also issued, with the size and exercise price set by a prior agreement.
Closing and revenue royalty provisions
The closing is expected on or about Aug. 17, 2026. The sale relied on exemptions under Section 4(a)(2) of the Securities Act or Rule 506(b).
3i and other investors are also to receive cash royalties totaling 5% of Velocity Bioworks gross revenue from third parties for 10 years.
